Simple jQuery Dropdowns

Browsing by Author Janssen

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)
5-Jun-2017Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>*</sup>Tadeusz Robak; Huiqiang Huang; Jie Jin; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Juliana Pereira; Jiri Mayer; Xiaonan Hong; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Helgi van de Velde; Franco Cavalli; Medical University of Lodz; Sun Yat-Sen University Cancer Center; Zhejiang University School of Medicine; Beijing Cancer Hospital; West China Hospital of Sichuan University; Lobachevsky State University of Nizhni Novgorod; null; KU Leuven– University Hospital Leuven; Mahidol University; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences; Universidade de Sao Paulo - USP; Fakultni Nemocnice Brno; Fudan University Shanghai Cancer Center; Tokyo Metropolitan Komagome Hospital; Janssen; Janssen Research and Development; Takeda Oncology; Ospedale San Giovanni
5-Mar-2015Bortezomib-based therapy for newly diagnosed mantle-cell lymphomaTadeusz Robak; Huiqiang Huang; Jie Jin; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Julia Alexeeva; Juliana Pereira; Johannes Drach; Jiri Mayer; Xiaonan Hong; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Helgi Van De Velde; Franco Cavalli; Medical University of Lodz; Sun Yat-Sen University Cancer Center; Zhejiang University School of Medicine; Beijing Cancer Hospital; West China Hospital of Sichuan University; Fudan University Shanghai Cancer Center; Nizhny Novgorod Regional Hospital; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences; Federal Center of Heart; Cherkassy Regional Oncology Center; KU Leuven– University Hospital Leuven; Janssen Research and Development; Mahidol University; Universidade de Sao Paulo - USP; Medizinische Universitat Wien; Fakultni Nemocnice Brno; Tokyo Metropolitan Komagome Hospital; Janssen; Janssen Research and Development; Ospedale San Giovanni
1-Jan-2014Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)David A. Wohl; Chloe Orkin; Manuela Doroana; José H. Pilotto; Somnuek Sungkanuparph; Patrick Yeni; Simon Vanveggel; Henri Deckx; Katia Boven; The University of North Carolina at Chapel Hill; Barts and The London NHS Trust; Santa Maria Hospital, Lisbon; Hospital Geral de Rio de Janeiro; Mahidol University; Hopital Bichat-Claude-Bernard AP-HP; Janssen Infectious Diseases BVBA; Janssen
1-Jan-2014Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO studyGareth Tudor-Williams; Pedro Cahn; Kulkanya Chokephaibulkit; Jan Fourie; Chris Karatzios; S. Dincq; M. Opsomer; T. N. Kakuda; S. Nijs; L. Tambuyzer; F. L. Tomaka; Rosa Bologna; Esaú João; José Henrique Pilotto; Marisa Mussi-Pinhata; Jorge Pinto; Normand Lapointe; Albert Faye; Kamila Kebaili; Steven Welch; Stefania Bernardi; Luisa Galli; Carlo Giaquinto; Nicola Principi; Gian Vincenzo Zuccotti; Henriette J. Scherpbier; Laura Marques; Isabel Soares; Margarida Tavares; Midnela Acevedo; Dan Duiculescu; Sorin Rugina; Gulam H. Latiff; Claudia Fortuny; Juan Antonio Leon Leal; Marissa Navarro; Jose T. Ramos; Tawee Chotpitayasunondh; Pope Kosalaraksa; Kiat Ruxrungtham; Jacobo Abadi; Tess Barton; William Borkowsy; Janet Chen; Joseph Church; Patricia Flynn; Sohail Rana; Richard Rutstein; Leonard Weiner; Imperial College London; Fundacion Huesped; Mahidol University; Dr Jan Fourie Medical Practice; Centre universitaire de sante McGill; Janssen Infectious Diseases BVBA; Janssen
21-Jul-2018Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch; Frank L. Tomaka; Frank Wegmann; Daniel J. Stieh; Galit Alter; Merlin L. Robb; Nelson L. Michael; Lauren Peter; Joseph P. Nkolola; Erica N. Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E. Stephenson; Wenjun Li; Bette Korber; Georgia D. Tomaras; David C. Montefiori; Glenda Gray; Nicole Frahm; M. Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G. Pau; Hanneke Schuitemaker; Janssen Vaccines &amp; Prevention B.V.; Centre for the AIDS Programme of Research in South Africa; International AIDS Vaccine Initiative; Makerere University; Janssen; Massachusetts Institute of Technology; Miami Research Associates; National Institute of Allergy and Infectious Diseases; Brigham and Women's Hospital; University of Witwatersrand; HJF; Walter Reed Army Institute of Research; Mahidol University; University of Colorado at Denver; Duke University; Los Alamos National Laboratory; Royal Thai Army; Fred Hutchinson Cancer Research Center; Harvard Medical School; University of Massachusetts Medical School; Optimal Research LLC; Tekton Research; Janssen Infectious Diseases; Rwanda Zambia HIV Research Group
1-Nov-2018Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 studyTadeusz Robak; Jie Jin; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Johannes Drach; Markus Raderer; Jiri Mayer; Juliana Pereira; Gayane Tumyan; Rumiko Okamoto; Susumu Nakahara; Peter Hu; Carlos Appiani; Sepideh Nemat; Franco Cavalli; Achiel Van Hoof; Adriana Sheliga; Adriana Teixeira; Akihiro Tomita; Albert Oriol Rocafiguera; Alexander Suvorov; Alexy Kuzmin; Ali Khojasteh; Amel Mezlini; Anatoly Golenkov; Andre Bosly; Andrew Belch; Ann Van De Velde; Árpád Illes; Ashis Mukhopadhyay; Balkis Meddeb; Bernard De Prijck; Bernardo Garichochea; Bulent Undar; Caballero Gabarrón; Carmen Cao; Carmino Souza; Charles Farber; Cheol Won Suh; Cristina Ileana Burcoveanu; Cristina Ligia Cebotaru; Cristina Ligia Truica; Dai Maruyama; David Belada; Dina Ben Yehuda; Dmitry Udovitsa; Dolores; Enrica Morra; Ernst Späth-Schwalbe; Eva Gonzalez-Barca; Evgenii Osmanov; Francisco Javier Capote; Fritz Offner; Galvez Cardenas; Georg Heß; Georgii Manikhas; Govind Babu; Grigoriy Rekhtman; Guiseppe Rossi; Herlander Marques; Horia Bumbea; Huaqing Wang; Huiqiang Huang; Ilseung Choi; Irina Bulavina; Irina Lysenko; Irit Avivi; Iryna Kryachok; Jan Maciej Zaucha; Jan Novak; Joaquín Díaz; Judit Demeter; Julia Alexeeva; Jun Zhu; Kateryna Vilchevskaya; Kenichi Ishizawa; Kenny Mauricio; Kensei Tobinai; Kiyoshi Ando; Kudrat Abdulkadryrov; Lee Yung Shih; Lyudmila Kuzina; Mahmut Gumus; Maike De Wit; Marcelo Capra; Margarida Marques; Marina Golubeva; Mario Ojeda-Uribe; Maryna Kyselyova; Masafumi Taniwaki; Massimo Federico; Michael Crump; Michele Baccarani; Michinori Ogura; Miklós Egyed; Miklos Udvardy; Mitsutoshi Kurosawa; Naokuni Uike; Nuriet Khuageva; The First Affiliated Hospital, Zhejiang University School of Medicine; Cherkassy Regional Oncology Center; Janssen Research &amp; Development; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences; KU Leuven– University Hospital Leuven; Masaryk University; Janssen; Allgemeines KrankenHaus Wien; Ospedale San Giovanni; Medizinische Universitat Wien; Faculty of Medicine, Siriraj Hospital, Mahidol University; Universidade de Sao Paulo - USP; Medical University of Lodz; Janssen Pharmaceutical; Chibanishi General Hospital